Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Prospective Multicenter Clinical Study of Venetoclax Combined With Hypomethylating Agents and Subcutaneous Cytarabine in Induction Therapy for CEBPA-Mutated Acute Myeloid Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07451912
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:17.607614+00:00
Published At
2026-03-05T00:00:00+00:00
Record Updated At
2026-03-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia (AML)", "CEBPA Mutation", "Unfit, New-diagnosis AML"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-05"
protocolSection.identificationModule.nctId
"NCT07451912"
protocolSection.identificationModule.officialTitle
"Prospective Multicenter Clinical Study of Venetoclax Combined With Hypomethylating Agents and Subcutaneous Cytarabine in Induction Therapy for CEBPA-Mutated Acute Myeloid Leukemia"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Myeloid Leukemia (AML) (protocolSection.conditionsModule.conditions)
  • CEBPA Mutation (protocolSection.conditionsModule.conditions)
  • Unfit, New-diagnosis AML (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.